Subscribe To
IMGN / ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
Content Topics
Immunogen
Announces
Webcast
Presentation
41st
Annual
Morgan
Healthcare
Conference
Stock
IMGN
IMGN News
By Zacks Investment Research
November 3, 2023
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The compan more_horizontal
By Seeking Alpha
October 31, 2023
Analyzing The Acquisition Potential Of ImmunoGen
ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European more_horizontal
By Schaeffers Research
September 1, 2023
3 Examples of How Moneyness Impacts Options Trading
Subscribers to Chart of the Week received this commentary on Sunday, August 27. more_horizontal
By Seeking Alpha
August 29, 2023
ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?
Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuxi more_horizontal
By Market Watch
August 28, 2023
ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical
Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with more_horizontal
By Schaeffers Research
August 8, 2023
Options Bears Break Bank With Biotech Stock Puts
Subscribers to Schaeffer's Event Trader service scored a 272% profit with our ImmunoGen, Inc. (NASDAQ:IMGN) August 17 put recommendation. more_horizontal
By Zacks Investment Research
July 31, 2023
ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates
ImmunoGen (IMGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0 more_horizontal
By Zacks Investment Research
July 17, 2023
ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors
ImmunoGen (IMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IMGN broke throug more_horizontal